P476: Using small bowel and colon video capsule endoscopy to optimise Crohn’s disease therapy may improve patient quality of lifeECCO '18 Vienna
2018
P477: The efficacy of adalimumab for the treatment of Korean patients with ulcerative colitis and predictors of response: Preliminary resultsECCO '18 Vienna
2018
P478: Treatment with ferric maltol associated with improvements in quality of life for IBD patients with iron deficiency anaemiaECCO '18 Vienna
2018
P479: Quality of care and outcomes in a tertiary hospital inflammatory bowel disease (IBD) centre: Monitoring and treatment algorithms during follow-upECCO '18 Vienna
2018
P480: Effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced diarrhoea/colitisECCO '18 Vienna
2018
P481: Induction treatment with subcutaneous rather than intravenous ustekinumab is associated with comparable circulating drugs levels and early clinical responseECCO '18 Vienna
2018
P482: Transanal minimally invasive proctectomy (TaMIP) in patients with inflammatory bowel diseases (IBD) within the TaTME international databaseECCO '18 Vienna
2018
P484: Infliximab and vedolizumab show a different effect on clot formation in inflammatory bowel disease patientsECCO '18 Vienna
2018
P486: Response to vedolizumab therapy in patients with inflammatory bowel disease: Impact of drug levels, anti-drug antibodies and α4β7 target occupancyECCO '18 Vienna
2018
P487: Tofacitinib for the treatment of ulcerative colitis: Analysis of infection rates from the OCTAVE clinical programmeECCO '18 Vienna
2018
P488: Efficacy of pre-operative oral antibiotic prophylaxis for the prevention of wound infections in patients with Crohn's diseaseECCO '18 Vienna
2018
P493: Comparison of the efficacy of infliximab biosimilar (Remsima®) vs. infliximab original (Remicade®) in patients with inflammatory bowel diseaseECCO '18 Vienna
2018